Sphera Funds Management’s LAVA Therapeutics LVTX Stock Holding History

Sphera Funds Management’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-48,420	Closed	-$61.5K	–	121
2025 Q1	$61.5K	Sell	48,420 -77,908	-62%	-$86.7K	0.01%	113
2024 Q4	$120K	Sell	126,328 -20,129	-14%	-$31.6K	0.02%	105
2024 Q3	$243K	Sell	146,457 -221,125	-60%	-$405K	0.04%	111
2024 Q2	$662K	Hold	367,582	–	–	0.09%	110
2024 Q1	$1.22M	Buy	+367,582	New	+$809K	0.17%	93
2022 Q1	–	Sell	-137,857	Closed	-$758K	–	85
2021 Q4	$758K	Sell	137,857 -77,502	-36%	-$508K	0.08%	88
2021 Q3	$1.27M	Hold	215,359	–	–	0.11%	101
2021 Q2	$2.34M	Buy	215,359 +1,465	+0.7%	+$18.2K	0.16%	104
2021 Q1	$3.25M	Buy	+213,894	New	+$2.94M	0.25%	92

Other funds holding LVTX

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return

PFA

Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sphera Funds Management's LVTX Position: Q2 2025 in Review

Sphera Funds Management sold out of LAVA Therapeutics (LVTX) in Q2 2025, closing a stake of 48,420 shares — an estimated $61.5K sold.

Sphera Funds Management first reported a position in LVTX in Q1 2021 and held it in 9 quarters. The position peaked at $3.25M in Q1 2021. 19 funds tracked by Wall St. Rank hold LVTX as of Q2 2025.

Sphera Funds Management reported no remaining LAVA Therapeutics position as of Q2 2025 after selling out during the quarter.
Sphera Funds Management sold 48,420 LAVA Therapeutics shares in Q2 2025, an estimated $61.5K.
Sphera Funds Management first reported a position in LAVA Therapeutics in Q1 2021 and held it in 9 quarters.
Sphera Funds Management's LAVA Therapeutics position peaked at $3.25M in Q1 2021.
19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.